作为CDK2抑制剂和抗癌剂的氧化-西醇混合物:设计,合成和生物评估
1Chemistry of Natural and Microbial Products Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre, Dokki, P.O. 12622, Cairo, Egypt. ht.abdel-mohsen@nrc.sci.eg.
BMC chemistry
|September 13, 2024
概括
合成了新的氧醇-西醇混合物,以准CDK2用于癌症治疗. 化合物9o显示出显著的抗癌活性,阻止细胞循环和诱导细胞亡,具有有利的ADME特性用于进一步开发.
科学领域:
- 药用化学 医学化学
- 有机合成 有机合成
- 癌症治疗方法 癌症治疗方法
背景情况:
- 牛津醇和西醇的支架因其抗癌潜力而得到认可.
- 向循环素依赖性激酶2 (CDK2) 是癌症治疗中的一个验证的策略.
- 分子杂交为开发新型抗癌药物提供了合理的方法.
研究的目的:
- 设计和合成新型的氧醇-二醇混合物.
- 为了评估这些混合体对NCI癌细胞系的抗癌活性.
- 为了研究最强大的混合向CDK2.2的作用机制.
主要方法:
- 通过分子杂交,合成氧醇-佐醇杂交物.
- 在体外评估增长抑制和细胞毒性活性.
- 细胞周期分析和细胞亡/亡试验.
- 对CDK2.2的酶抑制测定.
- 分子对接模拟. 分子对接模拟.
主要成果:
- 一系列的氧醇-西醇混合物 (9a-r) 已成功合成.
- 化合物9o表现出强烈的细胞毒性活性 (GI50 = 2.02 μM),并在DU145细胞中诱导G1细胞周期停止,细胞亡和亡.
- 混合体9b,9f和9o显示出显著的CDK2抑制 (IC50分别为0.70,0.20和0.21μM).
- 分子对接证实了CDK2 ATP结合口袋内的化合物9o的有利结合相互作用.
- 合成的混合体显示了可以接受的ADME特性.
结论:
- 这种新型的氧醇 - 西醇混合物显示出有前途的抗癌药物,其向的目标是CDK2.
- 化合物9o是进一步优化的一个有力的领先候选人.
- 这项研究验证了分子杂交作为发现新的癌症治疗方法的有效策略.
更多相关视频
相关概念视频
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Positive Regulator Molecules
5.4K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.4K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Electron Transport Chain: Complex I and II
12.2K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
12.2K


